Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

  • Christian RolfoEmail author
  • Judith de Vos-Geelen
  • Nicolas Isambert
  • L. Rhoda Molife
  • Jan H. M. Schellens
  • Jacques De Grève
  • Luc Dirix
  • Peter Grundtvig-Sørensen
  • Guy Jerusalem
  • Karin Leunen
  • Morten Mau-Sørensen
  • Ruth Plummer
  • Maria Learoyd
  • Wendy Bannister
  • Anitra Fielding
  • Alain Ravaud
Original Research Article



Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.


This phase I open-label study assessed the pharmacokinetics, safety and tolerability of single-dose, oral 300-mg olaparib tablets in adults (aged 18–75 years) with solid tumours. Patients had normal renal function, or mild or moderate renal impairment (estimated creatinine clearance ≥ 81, 51–80 or 31–50 mL/min, respectively). Blood was collected for 96 h, and urine samples collected for 24 h post-dose. Patients could continue taking olaparib 300 mg twice daily for a long-term safety assessment.


Overall, 44 patients received one or more doses of olaparib and 38 were included in the pharmacokinetic assessment. Patients with mild renal impairment had an area under the curve geometric least-squares mean ratio of 1.24 (90% confidence interval 1.06–1.47) and a geometric least-squares mean maximum plasma concentration ratio of 1.15 (90% confidence interval 1.04–1.27) vs. those with normal renal function. In patients with moderate renal impairment, the geometric least-squares mean ratio for the area under the curve was 1.44 (90% confidence interval 1.10–1.89) and for the maximum plasma concentration was 1.26 (90% confidence interval 1.06–1.48) vs. those with normal renal function. No new safety signals were detected in patients with mild or moderate renal impairment.


In patients with mild renal impairment, the small increase in exposure to olaparib was not considered clinically relevant. In patients with moderate renal impairment, exposure to olaparib increased by 44%; thus, these patients should be carefully monitored and the tablet dose should be adjusted to 200 mg twice daily.

Clinical Trials Registration




The authors thank the patients, their families, and all investigators and study personnel involved. Ruth Plummer and L. Rhoda Molife acknowledge that The Royal Marsden Hospital and Northern Centre of Cancer Care are funded by Cancer Research UK and the Department of Health (England) as Experimental Cancer Medicine Centres. Medical writing assistance was provided by Kristin Luehders PhD and Claire Routley PhD from Mudskipper Business Ltd, funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).

Author Contributions

All authors were involved in the obtaining, analysis and/or interpretation of data, drafting of the manuscript, critical revisions of the manuscript for important intellectual content, and approval of the final version.

Compliance with Ethical Standards


This study was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and MSD. AstraZeneca was involved in the study design, data collection, data analysis and data interpretation. MSD also provided input into data interpretation. Medical writing support was funded by AstraZeneca and MSD.

Conflict of interest

Christian Rolfo has received research grants from OncoDNA and consulting fees/honorarium from Mylan, and has participated in speaker bureaus for MSD, Novartis and Guardant Health. Judith de Vos-Geelen, Nicolas Isambert, L. Rhoda Molife, Peter Grundtvig-Sørensen, Karin Leunen, Ruth Plummer, Luc Dirix and Alain Ravaud have no conflicts of interest that are directly relevant to the content of this article. Jan H.M. Schellens is employed by and holds stock in Modra Pharmaceuticals, has a patent with oral taxanes and has a consultancy with Debiopharm. Morten Mau-Sørensen has received a research grant from AstraZeneca. Jacques De Grève has received a research grant from AstraZeneca, has attended advisory boards for AstraZeneca and is a board member of the AstraZeneca Foundation in Belgium. Guy Jerusalem has received research grants from Roche and Novartis, and consulting fees/honorarium from Novartis, Celgene, Roche, Amgen, Pfizer, Bristol-Myers Squibb, Lilly, Puma Biotech, AstraZeneca, Daiichi Sankyo and AbbVie. Maria Learoyd and Anitra Fielding are employees of, and hold stock in AstraZeneca. Wendy Bannister is a contractor for AstraZeneca.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Data accessibility

Data underlying the findings described in this article may be obtained in accordance with AstraZeneca’s data sharing policy described at:


  1. 1.
    Gunderson CC, Moore KN. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Future Oncol. 2015;11:747–57.CrossRefGoogle Scholar
  2. 2.
    European Medicines Agency. Lynparza summary of product characteristics. 2014. Accessed 03 Jul 2018.
  3. 3.
    US FDA. Lynparza (olaparib) capsules, for oral use: initial US approval. 2014. Accessed 05 Dec 2018.
  4. 4.
    Mateo J, Moreno V, Gupta A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol. 2016;11:401–15.CrossRefGoogle Scholar
  5. 5.
    US FDA. Lynparza (olaparib) tablets, for oral use. Prescribing information. 2018. Accessed 05 Dec 2018.
  6. 6.
    European Medicines Agency. CHMP assessment report on extension of marketing authorisation grouped with a variation: Lynparza. 2018. Accessed 05 Dec 2018.
  7. 7.
    Ang JE, Clarkson-Jones JA, Swaisland H, et al. A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. Eur J Cancer Suppl. 2010;8:128–9.CrossRefGoogle Scholar
  8. 8.
    Shahinian VB, Bahl A, Niepel D, et al. Considering renal risk while managing cancer. Cancer Manag Res. 2017;9:167–78.CrossRefGoogle Scholar
  9. 9.
    Zhou D, Li J, Bui K, et al. Bridging olaparib capsule and tablet formulations using population pharmacokinetic meta-analysis in oncology patients. Clin Pharmacokinet. 2018. (Epub ahead of print).Google Scholar
  10. 10.
    European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2015. Accessed 05 Dec 2018.
  11. 11.
    European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2014. Accessed 05 Dec 2018.
  12. 12.
    Zhou D, Li J, Learoyd M, et al. Efficacy and safety exposure-response analysis of olaparib capsule and tablet formulations in oncology patients. Clin Pharmacol Ther. 2018. (Epub ahead of print).Google Scholar
  13. 13.
    Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.CrossRefGoogle Scholar
  14. 14.
    Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Christian Rolfo
    • 1
    Email author
  • Judith de Vos-Geelen
    • 2
  • Nicolas Isambert
    • 3
  • L. Rhoda Molife
    • 4
    • 18
  • Jan H. M. Schellens
    • 5
    • 6
  • Jacques De Grève
    • 7
  • Luc Dirix
    • 8
  • Peter Grundtvig-Sørensen
    • 9
  • Guy Jerusalem
    • 10
  • Karin Leunen
    • 11
  • Morten Mau-Sørensen
    • 12
  • Ruth Plummer
    • 13
  • Maria Learoyd
    • 14
  • Wendy Bannister
    • 15
  • Anitra Fielding
    • 16
  • Alain Ravaud
    • 17
  1. 1.University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterBaltimoreUSA
  2. 2.Department of Medical Oncology, GROW-School for Oncology and Developmental BiologyMaastricht University Medical CenterMaastrichtThe Netherlands
  3. 3.Centre Georges François LeclercDijonFrance
  4. 4.Royal Marsden HospitalLondonUK
  5. 5.The Netherlands Cancer InstituteAmsterdamThe Netherlands
  6. 6.Utrecht Institute for Pharmaceutical Sciences, Utrecht UniversityUtrechtThe Netherlands
  7. 7.Medical OncologyUniversitair Ziekenhuis BrusselBrusselsBelgium
  8. 8.GZA Ziekenhuizen-Campus Sint AugustinusWilrijkBelgium
  9. 9.Herlev HospitalHerlevDenmark
  10. 10.Centre Hospitalier Universitaire du Sart Tilman, Liège UniversityLiègeBelgium
  11. 11.UZ Leuven GasthuisbergLeuvenBelgium
  12. 12.Department of OncologyRigshospitaletCopenhagenDenmark
  13. 13.Northern Centre of Cancer CareNewcastleUK
  14. 14.AstraZenecaCambridgeUK
  15. 15.PHASTARLondonUK
  16. 16.AstraZenecaMacclesfieldUK
  17. 17.Hôpital Saint André, Bordeaux University HospitalBordeauxFrance
  18. 18.MSDLondonUK

Personalised recommendations